RxDoctor Payments Data

Taryn Leroy, MD

Orthopaedic Surgery of the Spine · Boston, MANPI 1538690375

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (41.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Spineart USA Inc at 27.8% of the total. Reporting peaked in 2024 at $14,720 and has fallen 59.3% since, to $5,992 in 2025.

$35,973in general payments, 2019–2025

Across 221 payments — averaging $162.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spineart USA Inc$10K
  • Depuy Synthes Products, Inc.$5K
  • Medtronic$5K
  • Stryker$3K
  • Alphatec Spine, Inc$3K
  • Globus Medical$2K
  • plus $7K from 17 others

What the payments were for

  • Consulting fees$5,34815%
  • Grants$1,3224%
  • Travel & lodging$14,86041%
  • Food & beverage$13,61938%
  • Education$8242%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,973 in reported general payments places this provider in the 60th percentile of 28 orthopaedic surgery of the spine providers in Massachusetts.

See all orthopaedic surgery of the spine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$122,275
Medicare patients
147
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl47$241
Methocarbamol13$47

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →